A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition.
Aged
Blood Gas Analysis
Blood Glucose
/ analysis
Diabetes Mellitus, Type 2
/ complications
Diabetic Ketoacidosis
/ complications
Humans
Hypertension
/ complications
Hypoglycemic Agents
/ adverse effects
Intensive Care Units
Male
Patient Admission
Sodium-Glucose Transporter 2
/ physiology
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Journal
Journal of critical care
ISSN: 1557-8615
Titre abrégé: J Crit Care
Pays: United States
ID NLM: 8610642
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
14
05
2019
revised:
12
11
2019
accepted:
09
12
2019
pubmed:
3
2
2020
medline:
18
5
2021
entrez:
3
2
2020
Statut:
ppublish
Résumé
Sodium glucose cotransporter 2 (SGLT2) inhibitors are the latest class of oral hypoglycaemic agents approved to treat type II diabetes. Their use is increasing and as such more patients will present to critical care whilst on this treatment. However, there have been several case reports of euglycaemic diabetic ketoacidosis associated with the use of these agents. Under such circumstances the blood glucose is often normal or only moderately elevated and hence the diagnosis may be delayed resulting in inappropriate therapy. In this review we describe a case of SGLT2 mediated ketoacidosis who presented to our intensive care unit, discuss the proposed pathophysiology behind this development of ketoacidosis as well as its potential prevention, management and treatment.
Identifiants
pubmed: 32007835
pii: S0883-9441(19)30712-9
doi: 10.1016/j.jcrc.2019.12.007
pii:
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
SLC5A2 protein, human
0
Sodium-Glucose Transporter 2
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-22Informations de copyright
Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.